康泰生物 reported revenue of ¥1.27B for the period ended 2026-06-30, -8.6% year on year. Net income was ¥0.05B, a 3.7% net margin on a 71.3% gross margin. The largest revenue line is 自主产品-非免疫规划疫苗 at 93% of the total. Free cash flow for the period was ¥0.07B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.27B | -8.6% |
| Gross profit | ¥0.91B | — |
| Operating income | ¥0.05B | — |
| Net income | ¥0.05B | +26.9% |
| Gross margin | 71.3% | Net margin 3.7% |
| Revenue Q/Q | +1.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| 自主产品-非免疫规划疫苗 | ¥1.18B | 92.8% |
| 自主产品-免疫规划疫苗 | ¥0.05B | 3.8% |
| 房屋租赁 | ¥0.04B | 3.1% |
| 其他业务 | ¥0.00B | 0.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.37B | 28.7% |
| R&D | ¥0.18B | 13.8% |
| SG&A | ¥0.59B | 46.3% |
| Tax & other | ¥-0.00B | -0.1% |
| Item | Amount |
|---|---|
| Total assets | ¥13.93B |
| Total liabilities | ¥4.27B |
| Shareholders' equity | ¥9.66B |
| Equity / assets | 69.4% |
| Operating cash flow | ¥0.12B |
| Capital expenditure | ¥0.05B |
| Free cash flow | ¥0.07B |
| Cash conversion (OCF / net income) | 52% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
飞荣达 ・ 立昂技术 ・ 长川科技 ・ 恒锋信息 ・ 金太阳 ・ 拓斯达 ・ 思特奇 ・ 汇纳科技 ・ 晨化股份 ・ 美力科技 ・ 宣亚国际 ・ 富瀚微
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies